SHANGHAI, July 16,
2024 /PRNewswire/ -- Sanyou Biopharmaceuticals
(Shanghai) Co., Ltd. (hereinafter
referred to as "Sanyou Bio") has recently announced a significant
milestone in collaboration with Hangzhou Zhongmei Huadong
Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong
Medicine Co., Ltd. (SZ.000963, hereinafter referred to as
"Huadong Medicine"). The jointly
developed ADC drug, designated as project number SYHD001, has
successfully entered Phase I clinical trials. This important
milestone not only signifies substantial progress in the
collaboration between the two parties but also serves as a powerful
testimony to the cutting-edge technology platform of Sanyou
Bio.
SYHD001, as an ADC drug, presents extremely high technical
demands and development complexities. Sanyou Bio has laid a
solid foundation for the successful development of the drug from
the outset with its three innovative platforms for biologic
drugs: Super-trillion molecule discovery platform, Integrated
R&D platform, and Intelligent R&D platform. Sanyou Bio
completed the target research, raw material preparation, key
molecule generation, assisted and cooperated in completing ADC
conjugation and some in vitro and in vivo efficacy experiments, and
helped the client to quickly and efficiently screen out compliant,
high-expression, high-quality, and highly stable industrial cell
lines for the project, thereby ensuring high-quality production and
supply of ADC drugs and successfully promoting the project to
rapidly complete IND filing and enter Phase I clinical trials.
Dr. Guojun LANG, CEO of Sanyou Bio, said "We are extremely
honoured to collaborate with such an excellent partner as
Huadong Medicine to advance SYHD001
to the clinical stage. In the future development, Sanyou Bio will
continue to be committed to technological innovation and constantly
enhance the core competitiveness of our own technology platform. We
look forward to partnering with more collaborators to jointly
promote the development of the biopharmaceutical industry and
contribute more to the cause of human health."
Since its establishment in 2015, Sanyou Bio has provided
systematic solutions from target to IND to accelerate the drug
development process through five key categories of innovative
biologic drug R&D. The five key R&D stage services
include: Target Discovery and Raw Material Preparation, Molecule
Generation, Molecule Optimization, Pharmacology and Efficacy
Analysis, and Cell line Development and Production Process.
To date, Sanyou Bio has served 1,000+ pharmaceutical clients, 7
CPO projects have been obtained IND approval, 10+ projects are in
the preclinical R&D stage, 26 collaborative R&D projects
are progressing in manner. It has extensive experiences covering
100+ PCC projects and 300+ antibody drug discovery projects, and
has cooperated or assisted partners in publishing more than 50
papers, including top journals such as CNS.
About Huadong Medicine
Huadong Medicine Co., Ltd. (SZ.000963) was founded in 1993, with
its headquarters located in Hangzhou, Zhejiang. Adhering to the company value of
"Science Driven, Patient Centered", Huadong
Medicine has gone through over 20 years of development, and
has established a business presence covering the entire
pharmaceutical industry chain, with four major business segments:
pharmaceutical industry, pharmaceutical commerce, aesthetic
medicine, and industrial microorganism, and has grown into a large
comprehensive pharmaceutical listed company that integrates
pharmaceutical R&D, manufacturing, and distribution. In 2022,
Huadong Medicine achieved a revenue
of 37.715 billion yuan. With a
current employee count exceeding ten thousand, the company
possesses extensive commercial coverage and strong marketing
capabilities.
About Sanyou Bio
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech
biotechnology enterprise focusing on R&D and services of
innovative biologic drugs. Sanyou has built the 4C business
patterns that integrate "differentiated CRO, integrated CDO,
innovative CPO and characteristic CRS", to accomplish the mission
"to make the R&D easy for innovative biologics".
Sanyou has established an integrated innovative biologic drug
R&D laboratory with advanced facilities, and has a professional
team with the majority holding a Ph.D. or master degree. Sanyou has
built three industry-leading innovative technology platforms
featured by "super-trillion, integration, and intelligence", which
are comprised of more than 50 sub-platforms with the core
innovative super-trillion phage display platform, and supported by
platforms of material preparation, biologics discovery, molecule
optimization, in vitro and in vivo efficacy, production cell
line construction, upstream and downstream process development,
preclinical R&D, industrialization development, etc.
Sanyou's business network has expanded to all parts of the
world, including Asia, US and
Europe, and established branches
in Boston, Philadelphia, San
Diego and London. Sanyou
has established friendly business relationships with more than 1000
pharmaceutical companies, drug R&D institutions and diagnostics
companies worldwide. Sanyou received National-level certification
as a high-tech enterprise and a Specialized and Sophisticated
enterprise, and passed the ISO9001 quality assurance certification
and GB/T intellectual property management system certification.
View original
content:https://www.prnewswire.com/news-releases/sanyou-bio-collaborates-on-adc-drug-development-entering-phase-i-clinical-trials-302197951.html
SOURCE Sanyou Bio